Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2021

View Archived Issues

Anelixis begins phase II study of immunomodulation with AT-1501 in islet cell transplant

Selexis and Pandion to advance development of PT-627

Ventyx initiates dosing in phase I study of VTX-958 for autoimmune diseases

CohBar selects CB5138-3 as lead candidate for IPF and other fibrotic diseases

FDA clears initiation of phase I study of Meissa's COVID-19 vaccine candidate MV-014-212

Therapeutics Solutions plans to use StemVacs to treat COVID-19

T-Cure enters clinical research agreement to support phase I study of KK-LC-1 TCR therapy

Updated interim data reported from phase I/II study of GTB-3550 TriKE

Induced blastocysts are model for earliest development stages

AbbVie presents first-in-human data for ABBV-3373

Immatics reports data updates from ongoing phase I studies of its ACTengine candidates

New results presented for oral formulation of milvexian

Phase III data for omidubicel versus standard UCB in high-risk hematologic malignancies

Chinese phase I study begins with LPM-3480392

Ide-cel induces responses in heavily pretreated patients with refractory/relapsed myeloma

Lipopolysaccharides induce neural repair sweet spot

Data flaws sink current AI models for COVID-19 diagnosis

High blood fats, sugars alter antigen processing

Translate Bio reports second interim analysis of phase I/II trial of MRT-5005 for cystic fibrosis

Phase III topline data reported from ARISE-3 trial of RGN-259 in dry eye

PDE4 inhibitors divulged by Hubei Bio-Pharmaceutical, Humanwell Healthcare

Hefei Institutes of Physical Sciences presents new PDGFR-alpha and/or PDGFR-beta inhibitors

New hydroxyacid oxidase 1 inhibitors discovered at OxaluRx

HBV caspid assembly inhibitors patented by Tibet Tiansheng Taifeng Pharmaceutical

Gilead describes compounds for Filoviridae virus infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...